Angptl4 Upregulates Cholesterol Synthesis in Liver via Inhibition of LPL- and HL-Dependent Hepatic Cholesterol Uptake

L. Lichtenstein, J. F.P. Berbee, S. J. van Dijk, K. W. van Dijk, A. Bensadoun, I. P. Kema, P. J. Voshol, M. Muller, P. C.N. Rensen, S. Kersten
2007 Arteriosclerosis, Thrombosis and Vascular Biology  
Background-Dysregulation of plasma lipoprotein levels may increase the risk for atherosclerosis. Recently, angiopoietinlike protein 4, also known as fasting-induced adipose factor Fiaf, was uncovered as a novel modulator of plasma lipoprotein metabolism. Here we take advantage of the fasting-dependent phenotype of Angptl4-transgenic (Angptl4-Tg) mice to better characterize the metabolic function of Angptl4. Methods and Results-In 24-hour fasted mice, Angptl4 overexpression increased plasma
more » ... ycerides (TG) by 24-fold, which was attributable to elevated VLDL-, IDL/LDL-and HDL-TG content. Angptl4 overexpression decreased post-heparin LPL activity by stimulating conversion of endothelial-bound LPL dimers to circulating LPL monomers. In fasted but not fed state, Angptl4 overexpression severely impaired LPL-dependent plasma TG and cholesteryl ester clearance and subsequent uptake of fatty acids and cholesterol into tissues. Consequently, hepatic cholesterol content was significantly decreased, leading to universal upregulation of cholesterol and fatty acid synthesis pathways and increased rate of cholesterol synthesis. Conclusions-The hypertriglyceridemic effect of Angptl4 is attributable to inhibition of LPL-dependent VLDL lipolysis by converting LPL dimers to monomers, and Angptl4 upregulates cholesterol synthesis in liver secondary to inhibition of LPL-and HL-dependent hepatic cholesterol uptake. (Arterioscler Thromb Vasc Biol. 2007;27:000-000.)
doi:10.1161/atvbaha.107.151894 pmid:17761937 fatcat:a5zihdt2arhmfjax6nzihssmim